Symbotic (NASDAQ:SYM) Stock, Quote.Headers.trade-ideas

Symbotic

Symbotic Inc is an automation technology company that develops technologies to improve operating efficiencies in modern warehouses. The group develops, commercializes, and deploys innovative, end-to-end technology solutions that dramatically improve supply chain operations. Symbotic also automates the processing of pallets and cases in large warehouses or distribution centers for some of the retail and wholesale companies in the world. The company operates in two geographical regions the United States and Canada. Key revenue is generated from the United States.

Zaporizhzhia nuclear plant Photo by Ihor Bondarenko on Shutterstock

Large Cap

News

Movers

Trading Ideas

CART

CRWD

CVNA

DUOL

INTC

MBLY

MSFT

Fed&#39;s rate cut boosts tech, construction, industrial, machinery &amp; financial sectors. 11 top performers last week - are they in your portfolio?

Constellation Energy, Li Auto And Carvana Are Among Top 11 Large Cap Gainers Last Week (Sept 16-Sept 20): Are The Others In Your Portfolio?

Intraday Update

Markets

BELFB

BTBT

EWTX

MNSO

MSTR

NVDA

RZLV

TSLA

WULF

XPEV

Darden Restaurants Posts Q1 Results, Joins Tesla, Nvidia, XPeng And Other Big Stocks Moving Higher On Thursday

Screenshot 2024-09-03 at 2.35.29 PM

Equities

General

SFTBY

The company&#39;s value has now decreased to under $10 billion.

SoftBank, Walmart-Backed Robotics Giant Sees $9B Wipeout In Founder&#39;s Wealth After Company Stock That Surged Nearly 325% Last Year Takes A Steep Decline

Symbotic Inc

SYMBIO PHARMS LTD S/ADR by Symbio Pharmaceuticals Ltd

SymBio Pharmaceuticals Ltd

SYMPHONY INTERNATIONAL HOLDINGS ORD

Symbol

SYMBOLIC LOGIC INC by Symbolic Logic Inc.

Symbolic Logic Inc

SYMMETRY TECHNOLOGIES INC by Symmetry Technologies, Inc.

Symmetry Technologies Inc

SYMPHONY HOLDINGS ORD by Symphony Holdings, Ltd.

Symphony Holdings Ltd

SYMPHONY INTL HLDGS ORD by Symphony International Holdings Ltd.

Symphony International Holdings Ltd

Symrise AG

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Forthofix.com%2F&amp;esheet=54125379&amp;newsitemid=20240923211580&amp;lan=en-US&amp;anchor=Orthofix+Medical+Inc&amp;index=1&amp;md5=f980520f95bd1a9234c20487cdf8b284">Orthofix Medical Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>), a leading global medical technology company, today announced the presentation of new data supporting the use of Orthofix's proprietary Pulsed Electromagnetic Field (PEMF) stimulation to increase fusion rates as an adjunct to lumbar spine fusion surgery. Patients treated with the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbonegrowththerapy.com%2Ftherapies%2Fspinal-fusion%2Fspinalstim-lumbar-fusion%2F&amp;esheet=54125379&amp;newsitemid=20240923211580&amp;lan=en-US&amp;anchor=SpinalStim&amp;index=2&amp;md5=c26f0cc0fb348022b3ce0b675596e790">SpinalStim</a>&#x2122; bone growth therapy device demonstrated a high rate of successful fusion with significant improvements in pain, function and quality of life, despite having risk factors for pseudarthrosis.
The abstract will be presented by Dr. Marc Weinstein, an orthopedic spine surgeon at the Florida Orthopaedic Institute in Tampa, Florida, at the North American Spine Society (NASS) Annual Meeting in Chicago, IL, on September 25, during the Research and Innovation Showcase in the McCormick Place West Lobby of the McCormick Convention Center.
During the NASS annual meeting, Orthofix is also highlighting a variety of new products including the full market launch of OsteoStrand&#x2122; Plus C. A 100% bone-derived graft, OsteoStrand Plus C is comprised of Demineralized Bone Matrix (DBM) fibers and Accell&#x2122; Bone Matrix, a dispersed form of DBM that provides immediate release of growth factors upon implantation and increases the concentration of growth factors in the product, and cancellous chips. Used as a bone graft material in fusion applications, the OsteoStrand Plus C features improved graft packability relative to non-chip containing options – for a denser fill and to ensure minimal graft displacement. Additionally, Orthofix is announcing the launch of the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fm6disc.com%2F&amp;esheet=54125379&amp;newsitemid=20240923211580&amp;lan=en-US&amp;anchor=M6-C&amp;index=3&amp;md5=0f2300dfde3b2d3c8390c084ccf90edc">M6-C</a>&#x2122; Single-Use, Disposable Instrumentation sets, the first FDA-cleared, single-use, disposable instruments designed specifically for cervical disc arthroplasty.

OFIX

Orthofix Unveils New Spinal Fusion Products and Data, Highlighting Innovation at NASS Annual Meeting

Alibaba Group Holding&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) cloud computing services unit tapped&nbsp;Nvidia&nbsp;Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) to boost the&nbsp;autonomous driving&nbsp;experience for Chinese smart vehicle owners like Li Auto Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>),&nbsp;Great Wall Motor Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GWLLY#OTC">GWLLY</a>),&nbsp;Geely Auto&#8217;s&nbsp;ZEEKR Intelligent Technology Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>)&nbsp;and the EV unit of&nbsp;Xiaomi Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACY#OTC">XIACY</a>).
China is currently grappling with U.S. advanced semiconductor sanctions, which have restricted its access to Nvidia and other chipmakers&#8217; sophisticated artificial intelligence chips.
The U.S. chip companies opposed the U.S. move, citing the importance of China as a key semiconductor market. Alibaba has also voiced how the embargo has affected its AI endeavors.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/09/40923879/chinas-ymtc-makes-strides-in-chip-production-substitutes-asml-lam-research-tech-as-us-sanctions-bite" rel="noreferrer noopener">China&#8217;s YMTC Makes Strides in Chip Production; Substitutes ASML, Lam Research Tech As US Sanctions Bite: Report</a>
Alibaba Cloud showcased a large multimodal model (LMM) solution for automotive applications that it co-developed with its intelligent cockpit solution provider Banma Network Technology and Nvidia at the&nbsp;Apsara Conference, SCMP <a target="_blank" href="https://www.scmp.com/tech/big-tech/article/3279428/alibaba-nvidia-collaborate-advanced-autonomous-driving-solution-computing-services" rel="noreferrer noopener">reports</a>.
Alibaba Cloud integrated Qwen&#8217;s portfolio of proprietary large language models (LLMs) with Nvidia&#8217;s Drive AGX Orin platform for autonomous vehicles. The new LMM solution will enable in-car voice assistants to offer recommendations, and execute voice commands SCMP cites Alibaba Cloud.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23042244/newplot-17.png" alt="" class="wp-image-560553" style="width:920px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23042244/newplot-17.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23042244/newplot-17-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Nvidia and Alibaba Cloud look to Qwen LLMs to Nvidia&#8217;s Drive Thor, a centralized car computing platform.
Last week, Alibaba kicked off its <a target="_blank" href="https://www.benzinga.com/government/24/09/40936014/whats-going-on-with-chinese-tech-stocks-like-alibaba-pdd-on-thursday" rel="noreferrer noopener">Aspara Conference 2024</a>, showcasing 100 open-source AI models catering to applications and sectors ranging from automobiles to gaming and science research.
Chinese e-commerce juggernaut Alibaba Group Holding&#8217;s stock has risen over 1% in the last 12 months as the weak domestic economy and geopolitical tensions bite.
Investors can gain exposure to the stock through the Invesco Golden Dragon China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGJ#NASDAQ">PGJ</a>) and the Trust for Professional Managers ActivePassive International Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APIE#NYSE">APIE</a>).
Price Actions: BABA stock is up 0.85% at $89.04 premarket at last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40918150/alibaba-strikes-5-year-cloud-deal-with-indonesias-goto-delays-stake-divestment" target="_blank" rel="noreferrer noopener">Alibaba Strikes 5-Year Cloud Deal with Indonesia&#8217;s GoTo, Delays Stake Divestment</a></li>
</ul>
Photo by Fooksou Lamimo via Wikimedia Commons

Government

Regulations

Emerging Markets

Tech

Media

APIE

BABA

GWLLY

PowerShares Golden Dragon Halter USX China Portfolio

XIACY

Alibaba Teams Up With Nvidia to Supercharge EVs for Chinese Automakers: Report

RBC Capital analyst Gregory Renza initiates coverage on CG Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) with a Outperform rating and announces Price Target of $66.

Price Target

Initiation

Analyst Ratings

CGON

RBC Capital Initiates Coverage On CG Oncology with Outperform Rating, Announces Price Target of $66

<a href="https://www.globenewswire.com/Tracker?data=fTnauvHXrBinpqMkcNrU2jXyFxKpy_arXJzy_b5ASWO6l7AzfHZmmBhfNJU82qOIF0IRqYDITjpbTjTmYaz8lg==">uniQure</a> N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AMT-191, uniQure's investigational gene therapy for the treatment of Fabry disease, a rare, inherited genetic disease. In August 2024, uniQure announced the dosing of the first patient in its U.S., multi-center, open-label Phase I/IIa trial of AMT-191.
"This important designation highlights the need for new gene therapies like AMT-191 for patients with Fabry disease with the potential of delivering meaningful benefit given the suboptimal effectiveness of current chronic treatments," stated <a href="https://www.globenewswire.com/Tracker?data=XJHujD0zFsqCKj2AQYLx5YZE0M2jd1UjijpyNswg3uU3SriFCvwWI96vkEi8AA3le2sz_K36hMQhw9mjNc65v089QNwHSlUPjRhS5ybbM0ZoWv13dGsruJHJU5iG2D1r51IROOb0I1SREI2dhF2Cck4rSdmcC2GyFO4ZLtacqF9PhX4xHMVg625XkJYrftYl">Walid Abi-Saab, M.D., chief medical officer of uniQure</a>. "This designation supports our Phase I/IIa clinical trial and we look forward to rapidly generating clinical proof-of-concept data and providing initial data in 2025."
In patients with Fabry disease, a pathogenic variant in the galactosidase alpha (GLA) gene leads to α-galactosidase A (aGAL-A) enzyme deficiency, which in turn results in a progressive accumulation of lipids in multiple cell types, including kidney and heart cells, eventually resulting in a multi-system disorder. AMT-191 is a one-time intravenously administered investigational AAV5-based gene therapy that uses a proprietary, highly potent promoter to deliver a GLA transgene designed to target the liver to produce GLA protein.
The Phase I/IIa clinical trial of AMT-191 will be conducted in the United States. The multicenter, open-label trial consists of two cohorts with up to six adult male patients each: a low-dose cohort of 6x1013 gc/kg and a high-dose cohort of 3x1014 gc/kg delivered through a one-time intravenous infusion. Patients will continue to receive their regular enzyme replacement therapy until the criteria for withdrawal is met and will be followed for a period of 24 months. The trial will explore the safety, tolerability, and early signs of efficacy by measuring the expression of lysosomal enzyme aGLA-A. Additional details are available on <a href="https://www.globenewswire.com/Tracker?data=7KolP2h89egUHI8jH_Zo5bdDQZFzZM_38LjWTPDf3Kdw9gSQKRHs9DeKDUPU-daOSt9uPtk10WEjZA6W4qStkajilCQxvaD3HJzRrulXR-o=">www.clinicaltrials.gov</a> (NCT06270316).
The FDA's Orphan Drug Designation provides a special status for investigational drugs being developed for rare diseases considered to affect only up to 200,000 people in the United States. Orphan drug status provides certain incentives, including tax credits, grants and waiver of certain administrative fees for clinical trials as well as seven years of market exclusivity in the United States following drug approval.

QURE

FDA Grants Orphan Drug Status to uniQure's AMT-191, Aiming to Treat Fabry Disease

Biotech

Health Care

Stock Split

ORGS

Orgenesis Approves A 1-for-10 Reverse Stock Split Effective At 5:00 Pm Eastern Time On September 24

MIND Technology, Inc. ("MIND" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIND#NASDAQ">MIND</a>) announced today that its Seamap unit has received an order for a GunLink source controller amounting to approximately $5.1 million.&nbsp; Subsequent to July 31, 2024, the Company has received orders totaling approximately $7.9 million.
Mark Welker, Vice President of MIND and Seamap Managing Director, stated, "We are seeing strong demand for our GunLink source controllers. These most recent orders indicate the continuing demand across our family of source controller products. We expect to deliver a portion of these orders in this fiscal year; however, the majority will be delivered in our next fiscal year.&nbsp; In addition to the orders that we have in hand, we are pursuing a number of significant opportunities that we expect to bring to fruition in the coming weeks and months. We think our continuing backlog and pipeline of business bodes well for the balance of this fiscal year and next year as well."

MIND

MIND Technology's Seamap Unit Secures $5.1M GunLink Order, Expands Total to $7.9M

SKYE

Skye Bioscience Comments Regarding A Recent Announcement By Novo Nordisk On Phase 2a Topline Data With Monlunabant And, Reiterates Confidence In Its Nimacimab Clinical Development Plan, Says 16-week Top-line Weight Loss Data Validates Mechanism Of Action Targeting Peripheral CB1 Receptors

Federal Reserve

Minneapolis Fed President Kashkari Said Balance Of Risks Have Shifted Toward Risk Of Further Labor Market Weakening, Higher Unemployment; 50 BPS Rate Cut Was Right Decision, Reflects Progress On Inflation, Softening Of Labor Market

Invivyd, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today provided detailed virology data supporting previously communicated neutralization activity results, along with a genetic and structural analysis of past and present SARS-CoV-2 variant spike proteins, including the established molecular target of pemivibart.
As part of Invivyd's ongoing monitoring of antiviral activity, Invivyd contracts with LabCorp's Monogram Biosciences lab to provide independent, robust virology assessments in a consistent lineal chain that allows for consideration of potential changing pemivibart potency as SARS-CoV-2 evolves. Pemivibart potency against contemporary viruses KP.3.1.1 and LB.1 remains in-line with the totality of predominant variants dating back to 2022, including isolates identified during the conduct of the CANOPY Phase 3 clinical trial from late 2023 to early 2024. Data Table 1, below, provides relevant comparative values drawn from the PEMGARDA Healthcare Providers Fact Sheet.
"Quantitative neutralization assays exhibit marked intrinsic variability. Since discovery, pemivibart has exhibited impressively stable neutralization results across a wide range of SARS-CoV-2 variants, including and through contemporary variants tested," said Robert Allen, Ph.D., Chief Scientific Officer of Invivyd. "The values we observe thus far generally fall within the expected variability of the assay systems we employ."&nbsp;&nbsp;
Invivyd also provided an update to ongoing structural analysis showing no meaningful mutational change in the pemivibart binding site since the Omicron shift late in 2021. These data are presented in Figure 1 below. The pemivibart binding site is defined as a region of amino acid residues on the spike protein within 5 angstroms (5 Å) of the interaction between pemivibart and spike protein in a crystal structure and consists of 19 key amino acids. Invivyd's ongoing genetic and structural analyses of these residues provide the underlying biological rationale for the company's ongoing expectation for neutralization activity of pemivibart in the face of constant and convergent mutation in the SARS-CoV-2 spike protein. Analysis to date of all 19 amino acids presented below shows de minimis mutational change with ongoing stability to the binding site since the Omicron shift.
"To stay ahead of the curve, it is necessary to integrate data across multiple sources, including clinical and wastewater surveillance, as well as functional genomics. Invivyd's work over the last few years has achieved exactly that," said Kristian Andersen, Ph.D., a professor in the Department of Immunology and Microbiology at Scripps Research and member of Invivyd's scientific advisory board. "Continued surveillance of SARS-CoV-2 evolution is critically important to ensure that we can effectively counter the threat posed by the virus."

IVVD

Invivyd Shares New Data on Pemivibart's Neutralization of COVID Variants, Details Virus Evolution

U.S. index futures are modestly higher at the start of a new week as the rate cut euphoria fades and traders look ahead to the next key catalysts. The tech space could get a lift from <a href="https://www.benzinga.com/news/24/09/40975507/intels-stock-gains-in-pre-market-trading-following-reports-of-qualcomms-and-apollos-investment-offer">a potential lifeline for struggling Intel Corp.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) and traders may also look ahead to Micron Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) earnings report due later this week. FedEx Corp.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) annual shareholder meeting and conference presentations by companies could also be on traders&#8217; radar.
A few Fed speeches and private sector activity data due on Monday will also be of interest to the market, which has had an atypically strong September. China followed up with more cuts on Monday as the country strives to bring the struggling economy back on track.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>+0.24%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>+0.15%</td>
</tr>
<tr>
<td>Dow</td>
<td>+0.06%</td>
</tr>
<tr>
<td>R2K</td>
<td>+0.32%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday,&nbsp;the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.15% to $569.09 and the&nbsp;Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) climbed 0.27% to $483.06, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Cues From Last Week:
U.S. stocks recorded gains for the second straight week as the Fed&#8217;s 50 basis-point cut set the market on fire, although a session after the announcement. After a mixed start to the week, positive retail sales generated buying interest in the market on Tuesday. Sentiment soured on Wednesday despite the initial positive reaction to the rate cut and the major indices closed lower. 
Traders reacted with a lag to the rate cut, sending averages sharply higher on Thursday. The S&amp;P 500 Index and the Dow Jones Industrial Average scaled record highs in the session. Caution returned on Friday as the market closed the triple-witching session on a mixed note. The Dow built on its gains on Friday and ended at a new high.
&#8220;This might be a September rally to remember on Wall Street, as history is not on the side of September delivering many market rallies,&#8221; said fund manager Louis Navellier.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Weekly Performance (+/)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>+1.50%</td>
<td>17,948.32</td>
</tr>
<tr>
<td>S&amp;P 500 Index</td>
<td>+1.36%</td>
<td>5,702.55</td>
</tr>
<tr>
<td>Dow Industrials</td>
<td>+1.62%</td>
<td>42,063.36</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>+2.08%</td>
<td>2,227.89</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
The atypical September rally points to more gains ahead before the year ends, says Carson Group&#8217;s Chief Market Strategist Ryan Detrick. A new high for the S&amp;P 500 Index in September has meant an even better fourth quarter in the past, he said. The market has risen 19 out of 21 times and the average gain is nearly 5%, he said. If the new high was made in September, which also happens to be an election year, the fourth quarter is higher 100% of the time with an average gain of 6%.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">When the S&amp;P 500 makes a new high in September (like &#39;24) it appears Q4 does even better. In fact, higher 19 out of 21 times (90.4%) and up nearly 5% on avg. New highs in Sept of election year? Q4 higher 6 out of 6 and up nearly 6% on avg.
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1837903370494820836?ref_src=twsrc%5Etfw">September 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The S&amp;P 500 Index, which closed Friday&#8217;s session, just shy of an all-time high, is now above year-end price predictions of 70% of Wall Street analysts. This has rendered S&amp;P valuation slightly higher than the average number for the past five and past 10 years, FactSet data showed.
JPMorgan Global Investment Strategist&nbsp;Sarah Stillpass&nbsp;said in a report the September rate cut could bode well for equities. Since 1980, five of the 10 best years for the S&amp;P 500 happened when the Fed was cutting rates without a recession, she said. She also noted that the Fed has cut rates 12 times when the S&amp;P 500 was within 1% of its all-time high such as the current year. The market was higher one year later all 12 times, with a median return of 15%, she added.
See also: <a href="https://www.benzinga.com/money/best-futures-trading-software">Best Futures Trading Software</a>
Upcoming Economic Data:
A slew of Fed speeches and the core personal consumption expenditure index, which is part of the personal income and spending report, are the key data the market will likely look forward to in the unfolding week. Traders may also keep a close eye on the weekly jobless claims data, flash private sector activity readings from S&amp;P Global, a consumer confidence reading, the August durables goods orders data and a couple of housing market readings.
On Monday, Atlanta Fed President Raphael Bostic is scheduled to speak at 8 a.m. EDT, followed by Chicago Fed President Austan Goolsbee at 10:15 a.m. EDT and Minneapolis Fed President Neel Kashkari&nbsp;at 1 p.m. EDT.
S&amp;P Global will release its flash manufacturing and service sector purchasing managers&#8217; indices for September at 9:45 a.m. EDT. Economists, on average, expect the manufacturing purchasing managers&#8217; index to rise from 47.9 in August to 48.4 in September, suggesting the sector continued to contract. The service sector PMI is widely expected to hold steady at 55.4 compared to August&#8217;s 55.7.
The Treasury will auction three- and six-month notes at 11:30 a.m. EDT.
Stocks In Focus:
<ul>
<li>Intel rose about 3% <a href="https://www.benzinga.com/premarket">in premarket trading</a> amid reports that Apollo Global Management seeks to invest $5 billion in the chipmaker in return for an equity stake in the company. Incidentally, Qualcomm, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) is rumored to be interested in buying Intel.</li>
<li>Bitcoin&#8217;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rally is sending crypto-linked stocks higher on Monday.</li>
<li>Palantir Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) fell over 1.60% following a negative analyst action. The company will be added to the S&amp;P 500 Index, along with Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) and Erie Indemnity Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>).</li>
<li>AAR Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) is due to <a href="https://www.benzinga.com/calendars/earnings">announce its quarterly results after the market closes.</a></li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil and gold futures are modestly higher, with the latter trading near record territory. Bitcoin has gone past the $63.5K level. The 10-year Treasury note yield rose 1.1 points to 3.739%.
The Asian markets closed on a lackluster note, although the Japanese market remained closed for a public holiday. The People&#8217;s Bank of China announced a cut to its 14-day reverse repurchase rate, following up with the downward adjustments that began in July. Chinese central bank governor Pan Gongsheng will hold a press conference Tuesday on financial support for economic development, alongside two other officials, Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-09-23/china-announces-another-rate-cut-as-growth-slowdown-worsens">reported.</a>
European stocks also showed tentativeness as domestic traders digested weak private sector activity data from the region.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40974885/s-p-500-outpaces-wall-street-projections-as-year-end-nears-will-the-rally-hold">S&amp;P 500 Outpaces Wall Street Projections As Year-End Nears: Will The Rally Hold?</a></li>
</ul>
Photo via Shutterstock

Earnings

Futures

Previews

Economics

Pre-Market Outlook

$BTC

DELL

ERIE

PLTR

QCOM

Wall Street Eyes Modestly Positive Start As Atypical September Rally Generates Positive Sentiment, China Cuts Rate: Intel, Palantir, Bitcoin Make Huge Moves

<ul>
<li>Riot has agreed to withdraw its June 24, 2024 requisition, as amended, and to accept customary standstill provisions through the Bitfarms 2026 Annual Meeting, with certain exceptions.</li>
<li>The Company has provided Riot with certain rights (subject to certain exceptions) to purchase shares of the Company provided Riot holds&nbsp;15%&nbsp;or more of the outstanding common shares of the Company.</li>
</ul>

Management

BITF

RIOT

Bitfarms, Riot Platforms Enter Settlement Agreement In Advance Of Special Meeting; Andrés Finkielsztain Has Stepped Down From Bitfarms' Board, Amy Freedman To Join Board

ALKS

Alkermes Announced Plans To Present Clinical Data From Its Phase 1B Study Of ALKS 2680 In Patients With Narcolepsy Type 2 And Idiopathic Hypersomnia At The European Sleep Research Society Congress, Sleep Europe 2024

MoffettNathanson analyst Michael Nathanson initiates coverage on Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Neutral rating and announces Price Target of $100.

MoffettNathanson Initiates Coverage On Trade Desk with Neutral Rating, Announces Price Target of $100

<a href="https://www.globenewswire.com/Tracker?data=r4RuL-g8BiKVZqLRnMl8EGgAMp3MEvcuP1lhTYpiuoJgsZ1jahk_eeysIWLnQ1bAlIACdbq5BXPKTE0CscTH9fs6bHnXyXzwYWhIPkSFsL0=">Black Diamond Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported initial Phase 2 data demonstrating encouraging clinical responses and durability of BDTX-1535 in patients with relapsed/refractory epidermal growth factor receptor (EGFR)-mutant (EGFRm) non-small cell lung cancer (NSCLC).
"Patients often become resistant to osimertinib with the emergence of on-target resistance EGFR mutations," said Sergey Yurasov, M.D., Chief Medical Officer of Black Diamond Therapeutics. "Our preliminary Phase 2 data demonstrate the potential of BDTX-1535 to deliver durable responses for these patients."
"Patients with recurrent EGFRm NSCLC have few treatment options, with chemotherapy delivering limited benefit and significant toxicity, and initial Phase 2 data with BDTX-1535 look quite promising," said Danny Nguyen, M.D., <a href="https://www.globenewswire.com/Tracker?data=vlr3UZ7jREPq-nVuV_0_0C88uBRItoG_u2Pds2FLZhl6OdG7j4DTPUFysQY2y_LIjwyzqAqfOfpni53hE75snJRWUiN0k0RirbHBhXGxPKYSET-VNVVUwbCm2cnWyEzenhj0xWJvWFDh1oHU2wzxnXLBK7T4WBCokjmhe7dQL7lQDcWhMG63hpBMKrSRhrsiyEiYvQrw6wRSj8xyaeufaSI2us8FlQDhdtCYWaPgkus=">Assistant Clinical Professor, Department of Medical Oncology and Therapeutics Research at City of Hope</a>. "There is a significant unmet medical need for an effective and well-tolerated oral therapy for patients who progress on osimertinib, as well as newly diagnosed patients with non-classical mutations."
Phase 2 preliminary data overview:
The phase 2 trial began in August of 2023, and enrolled relapsed/refractory patients with non-classical EGFR mutations (NCMs) (Cohort 1) and those with C797S resistance mutations (Cohort 2). Safety assessment and dose selection were based upon the first 40 patients randomized to receive BDTX-1535 once daily at either 100 mg or 200 mg across both Cohorts. Preliminary response rate and durability were assessed in 27 patients at 200 mg with an August 17, 2024, data cutoff, including 22 response-evaluable patients who met protocol eligibility criteria.
Key takeaways:
<ul>
<li>200 mg daily selected for pivotal clinical development. Dose selection was based primarily on pharmacokinetics, safety and tolerability data from 20 patients at 100 mg, and 20 patients at 200 mg.</li>
<li>Favorable tolerability profile at 200 mg, consistent with prior BDTX-1535 clinical data. The majority of adverse events were mild or moderate, and no new safety signals were observed. The most common on-target treatment-related adverse events were rash (70%) and diarrhea (35%). There were 2 cases of grade 3 rash, and no reported cases of grade 4 rash or grade 3/4 diarrhea.</li>
<li>Preliminary objective response rate (ORR) of 42% achieved in 19 patients. For the 22 response-evaluable patients, the preliminary ORR was 36%. Nineteen of these 22 patients expressed known osimertinib resistance mutations: either C797S or P-loop alpha-C helix compressing (PACC, a major subset of NCMs). Of these 19 patients, 8 achieved a response (42%): 5 with a confirmed partial response (PR), including 1 patient who converted from a PR to an unconfirmed complete response (CR) at 8 months (and awaits confirmatory scan); and 3 with an unconfirmed PR at first scan and awaiting a confirmatory scan. An additional 9 patients experienced stable disease.</li>
<li>Encouraging durability observed, with duration of response (DOR) of approximately 8 months or more for first 3 patients with PR; 14 of 19 patients remain on therapy. Mean follow-up time is 4.7 months.</li>
</ul>
"We are pleased to see significant Phase 2 clinical activity and tolerability that are consistent with our Phase 1 results," said Mark Velleca, M.D., Ph.D., Chief Executive Officer of Black Diamond Therapeutics. "We believe that the activity observed in the recurrent setting can translate to robust clinical benefit in the first-line setting, and we look forward to sharing data from our trial in newly diagnosed patients in Q1 2025."
Black Diamond continues to enroll patients in the second- and third-line cohorts, as well as in the first-line setting for patients with non-classical EGFR mutations. In Q1 2025, the Company expects to disclose initial results from the first-line cohort and to outline potential registrational paths in the recurrent setting based on FDA feedback.

BDTX

Black Diamond Reports Phase 2 Results for BDTX-1535 in Lung Cancer, Targets FDA Approval Path

Lead investors, Delta Air Lines, Inc.,&nbsp;CK&nbsp;Wheels&nbsp;LLC, and Cox&nbsp;Investment Holdings,&nbsp;LLC, agreed to extend the lock-up restriction with respect to all their shares of common stock&nbsp;issued under the Investment and Investor Rights Agreement, for an additional year, until September&nbsp;20,&nbsp;2025.
In addition, Kore Capital LLC and funds managed by Whitebox&nbsp;Advisors LLC, agreed to extend the lock-up restriction with respect to&nbsp;72.5%&nbsp;of their shares until September&nbsp;20,&nbsp;2025.

Wheels Up Says Approximately 97.2% Of Lead Investor Shares Will Remain Subject To The Lock-up Restriction Until September 20, 2025

AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>), the world's trusted infrastructure consulting firm, today announced its selection by the City of Austin as the prime consultant for the expansion of the Walnut Creek Wastewater Treatment Plant (WWTP) in Austin, Texas. The project aims to improve the aging structure's operational and environmental features by increasing the plant's capacity from 75 million gallons per day (MGD) to 100 MGD. As the population of Austin grows, the upgrades will bolster the resiliency of the community's wastewater infrastructure while safeguarding its surrounding ecosystem.
"As our industry's leading Water consulting firm, we look forward to continuing our long-standing partnership with the City of Austin to ensure the Walnut Creek Expansion delivers state-of-the-art treatment capabilities to the local community," said Beverley Stinson, chief executive of AECOM's global Water business. "Our teams have established themselves as pioneers in the global push to advance highly efficient and cost effective nutrient removal, and will leverage this extensive expertise to enhance the plant and improve the effluent water quality to protect the environment, while meeting existing and future community demands."
The AECOM team's scope of work for the project includes process, mechanical, civil, electrical and structural engineering services to modernize and upgrade the existing infrastructure, while incorporating advanced operational and environmental features. The expansion will involve replacing aging equipment, constructing a new 25 MGD treatment train, and building a new 120-inch outfall line and structure. The project will also provide wet weather treatment with new 100 MGD cloth filters and build a flood wall to protect against 100-year floods in accordance with the National Weather Service's historic <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.austintexas.gov%2Fdepartment%2Fflood-risk-and-atlas-14&amp;esheet=54125161&amp;newsitemid=20240923628017&amp;lan=en-US&amp;anchor=Atlas+14&amp;index=1&amp;md5=f42d51c75c9b61534bc111d8082f631f">Atlas 14</a> flood risk study.
"AECOM has a longstanding partnership with the City of Austin, having designed substantial portions of the City's major water and wastewater treatment plants," said Matt Crane, chief executive of AECOM's U.S. West region. "Our expertise in complex treatment design will support an exceptionally resilient, sustainable facility, aligning with our Sustainable Legacies strategy to make a lasting positive impact through every project we undertake."
Originally built in 1977 with an 18 million gallon per day capacity, the Walnut Creek Wastewater Treatment Plant has since been expanded three times in 1987, 1990, and 2005 to reach its current capacity of 75 million gallons per day. The facility is expected to remain operational throughout the work.

AECOM to Lead Major Expansion of Austin's Walnut Creek Wastewater Plant, Boosting Capacity to 100 MGD

Tempur Sealy International, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPX#NYSE">TPX</a>, ", Company", or ", Tempur Sealy", )))) today provided an update with respect to the Company's agreement to acquire Mattress Firm Group Inc. ("Mattress Firm"), which is currently being challenged in federal court by the Federal Trade Commission ("FTC").
The litigation process continues to progress, with hearings currently scheduled to begin on November 12, 2024, and expected to last two weeks. The Company continues to believe that a successful litigation process can be completed in the coming months, which would allow the transaction to close in late 2024 or early 2025, consistent with previous expectations.
In conjunction with the planned Mattress Firm acquisition, Tempur Sealy has entered into a purchase agreement with MW SO Holdings Company, LLC ("Mattress Warehouse"), a leading independently owned bedding specialty retailer, for the sale of 73 Mattress Firm retail locations and the Company's Sleep Outfitters subsidiary, which includes 103 specialty mattress retail locations and seven distribution centers.
Mattress Warehouse is a multi-branded retailer offering a full array of mattresses at various price points. Tempur Sealy will continue to supply its Tempur-Pedic, Stearns &amp; Foster, and Sealy products to the divested Mattress Firm and Sleep Outfitters stores. The divestiture is subject to the closing of Tempur Sealy's acquisition of Mattress Firm and other customary closing conditions. It is expected to close approximately one quarter after the closing of the Mattress Firm transaction.
Company Chairman and CEO Scott Thompson commented, "As part of our engagement with the FTC on the proposed acquisition of Mattress Firm, we conducted a divestiture process, which led to an agreement with Mattress Warehouse, a company with extensive mattress retail experience, a strong capital base, and a capable leadership team."

Tempur Sealy Moves Forward with Mattress Firm Acquisition, FTC Court Hearings Set for November

Tempur Sealy intends to use the proceeds from the Term Loan B, together with cash available and proceeds from other debt, to fund the cash consideration for the previously announced acquisition of Mattress Firm Group Inc.. Tempur Sealy intends to draw on the Term Loan B concurrent with the closing of the Mattress Firm acquisition.

Tempur Sealy Launches Proposed Senior Secured Term Loan B Facility In An Aggregate Principal Amount Of Up To $1.6B

Keybanc analyst Jackson Ader maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Overweight and raises the price target from $300 to $345.

Keybanc Maintains Overweight on CrowdStrike Holdings, Raises Price Target to $345

Keybanc analyst Sangita Jain maintains Constellation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) with a Overweight and raises the price target from $230 to $265.

Keybanc Maintains Overweight on Constellation Energy, Raises Price Target to $265

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
In a new InvestorPlace presentation, &ldquo;The Next Wave of Breakout Stocks,&rdquo; host Chris Hurt admits he has been one of the unlucky ones. He admits to missing out on, among plenty of others, these breakout stocks:



<ul><li>Energy drink maker Celsius (NASDAQ:<a href="https://investorplace.com/stock-quotes/celh-stock-quote/">CELH</a>), which is up 1,400%</li>



<li>AI GPU superstar Nvidia (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/">NVDA</a>), up 1,000%</li>



<li>And robotics firm Symbotic (NASDAQ:<a href="https://investorplace.com/stock-quotes/sym-stock-quote/">SYM</a>), which has leaped 400%</li>
</ul>You might have missed out on these gains, too.



However, there&rsquo;s a good reason why picking these sorts of winners is so hard: They can look downright ugly before their breakouts.



In 2019, Celsius was a money-losing regional drink maker with no nationwide distribution network. Nvidia had just lost 50% of its value from the cryptocurrency hangover that same period. And in 2022, Symbotic looked more like a busted SPAC than the next AI superstar.



It&rsquo;s no wonder why Chris and thousands of others wanted to stay far, far away.



We&rsquo;re seeing the same story play out today. Last week, shares of some of the largest AI-focused firms tumbled as investors reconsidered their high-priced bets. Companies like chipmaker Intel (<a href="https://investorplace.com/stock-quotes/intc-stock-quote/">INTC</a>) have lost almost 50% in a month, which is why some people are comparing last week&rsquo;s volatility to 1987&rsquo;s &ldquo;Black Monday.&rdquo;



Things are ugly. And it&rsquo;s not clear which stocks to buy the dip on.



Fortunately, there&rsquo;s a solution. One that&rsquo;s taken years to develop. In his latest talk with InvestorPlace Chief Investment Analyst Luke Lango, Chris reveals how Luke and his team have created a quantitative-driven system that&rsquo;s able to cut through the &ldquo;ugliness&rdquo; and help them identify these diamonds-in-the-rough before they bounce back. It&rsquo;s called Prometheus, <a href="https://secure.investorplace.com/?cid=MKT803528&amp;eid=MKT811953&amp;step=start&amp;plcid=PLC213427">and you can learn more about it in their presentation here</a>.



Even better, many of the system&rsquo;s top picks are also the same ones our InvestorPlace.com writers have been eyeing. Together, we&rsquo;ve found a handful of companies that human and &ldquo;machine&rdquo; believe are set to rebound and potentially turn into breakout stocks.



<h2>Nvidia (NVDA)</h2>



Perhaps the greatest source of hand-wringing last week came from Nvidia, a company that many believed had grown too large, too quickly. It only took the chipmaker three months to move from a $2 trillion firm to a $3 trillion one earlier this year, which made the selloff equally violent. Last week&rsquo;s decline has now brought shares down 25% since their July peak &ndash; erasing almost that same trillion dollars from Nvidia&rsquo;s market value.



However, both Louis Navellier and Prometheus see an opportunity to buy the dip. As Louis bluntly puts it, <a href="https://investorplace.com/market360/2024/08/dont-let-talk-of-bubble-trouble-scare-you-off-nvidia-stock/'">don&rsquo;t let talk of &ldquo;bubble trouble&rdquo; scare you from Nvidia</a>:




It may be overstating it to say that NVDA is in &ldquo;bubble land.&rdquo; The GenAI boom took shape in early 2023. Since then, shares have surged by more than sevenfold.



However, earnings have gone up nearly tenfold during this time frame. In FY2023, Nvidia&rsquo;s earnings came at 18 cents per share. Over the trailing 12-month period, reported earnings have totaled $1.73 per share.




In other words, Nvidia&rsquo;s meteoritic rise has come with an even greater increase in profits. Shares of the company trade at just 25 times estimated 2025 earnings&hellip; hardly the stuff of bubbles. Earnings forecasts have also continued to increase, with the average analyst adding 3% to their earnings per share (<a href="https://investorplace.com/stock-quotes/eps-stock-quote/">EPS</a>) estimates over the past 30 days. This is historically a bullish sign of more gains to come.



Of course, there are some risks that Nvidia will fail to deliver on future earnings. Competition is rising among AI chip producers, just as data center players are facing mounting pressure to cut costs. But that&rsquo;s precisely why the stock has fallen 25% in the first place. Prometheus awards Nvidia a &gt;90 score, which suggests a rebound is likely over the next four weeks.



<h2>KLA (KLAC)</h2>



Shares of high-quality KLA (NASDAQ:<a href="https://investorplace.com/stock-quotes/klac-stock-quote/">KLAC</a>) have plunged 20% since July on similar concerns over AI chip demand. Investors are worried about data centers cutting semiconductor demand and have sold KLA along with lower-quality firms.



The Silicon Valley firm is one of the largest global manufacturers of wafer fabrication equipment for semiconductors, specializing in process control. It&rsquo;s an essential service that helps manufacturers inspect chips during research and production.



The complexity of KLA&rsquo;s equipment and relevant services means the company has incredible pricing power and scale. It&rsquo;s roughly four times larger than its closest competitor, according to analysts at Morningstar, and earns over 40% gross margins.



In June, InvestorPlace.com&rsquo;s Omor Ibne Ehsan called KLA a tech trailblazer that&rsquo;s <a href="https://investorplace.com/2024/06/7-stocks-to-buy-if-you-think-well-see-nasdaq-20k-in-2024/">paving the way in AI, 5G and Internet of Things</a>:




Although the firm&rsquo;s growth has moderated recently, I think the company&rsquo;s consistent ability to surpass Wall Street projections bodes well for its future prospects. As the semiconductor industry continues to boom, driven by insatiable demand for cutting-edge chips, KLAC is poised to thrive. If it maintains its momentum and the Nasdaq soars past 20,000, I wouldn&rsquo;t be surprised to see the stock catapult beyond the $1,000 mark.




The recent selloff now means Ehsan&rsquo;s $1,000 target price represents almost a 40% upside from current prices. The company scores a strong 88 with Prometheus, and analysts have raised their current-year earnings estimates by 5% over the past 30 days.



<h2>Microsoft (MSFT)</h2>



Joel Baglole writes this week that a <a href="https://investorplace.com/2024/08/take-advantage-of-the-tech-selloff-and-buy-microsoft-stock/">buying opportunity has finally opened up</a> with Microsoft (NASDAQ:<a href="https://investorplace.com/stock-quotes/msft-stock-quote/">MSFT</a>), a company that markets have sold off:




Microsoft delivered a Q2 print that was strong overall and exceeded Wall Street targets on the top and bottom lines. Most analysts raised their targets on Microsoft stock after the Q2 earnings were made public&hellip;



However, MSFT stock has been pulled lower since the beginning of July amid the broad pullback in technology securities. In the last month, Microsoft stock has declined 13%. This presents a golden opportunity to buy the dip in a best-in-class stock that has a track record of rewarding shareholders.




Essentially, Microsoft is beginning to catch up in enterprise-focused cloud computing &ndash; an area that Amazon.com (NASDAQ:<a href="https://investorplace.com/stock-quotes/amzn-stock-quote/">AMZN</a>) once dominated. Azure cloud service revenues rose 29% in the quarter, well ahead of Amazon&rsquo;s 19% growth rate. It&rsquo;s an increasingly lucrative segment that&rsquo;s helped increase Microsoft&rsquo;s quarterly revenues by $4.5 billion. InvestorPlace.com&rsquo;s Faisal Humayun additionally notes that Microsoft&rsquo;s Azure AI <a href="https://investorplace.com/2024/08/3-technology-stocks-to-buy-after-a-20-30-correction/">could bring in as much as $200 billion in five years</a>, making it a solid firm to buy the dip.



Prometheus awards Microsoft a strong score of 88.



<h2>Symbotic (SYM)</h2>



Last month, InvestorPlace.com writer Eddie Pan noted that warehouse automation firm Symbotic had fallen 25% on weak guidance. (Yes, the same one that previously rose 400%.) He explains <a href="https://investorplace.com/2024/07/symbotic-sym-stock-is-down-25-on-weak-guidance-whats-going-on-with-the-ai-darling/">what&rsquo;s going on with the AI darling</a>:




Guidance is where Symbotic struggled. The company guided for fourth-quarter revenue of between $455 million and $475 million and adjusted EBITDA between $28 million and $32 million. Analysts were expecting revenue of $516.84 million, meaning that the midpoint of Symbotic&rsquo;s revenue missed the target by a significant 10%.




A deeper read shows that revenue forecast cuts were a direct result of a planned in-sourcing initiative, which will decrease revenues in the near term and increase profits for the long run. Management realized that much of its outsourcing was costing the firm too much and has opted for slower, more profitable growth.



That&rsquo;s why Pan also notes that Wall Street analysts expect the Massachusetts-based firm to quickly recover.



The recent stock market selloff now provides a perfect opportunity to jump in on this high-potential stock. Prometheus award shares a score of 87.8, putting it in the top 2% of large-cap companies.



<h2>Intel (INTC)</h2>



Finally, our most contentious buy-the-dip pick this week is Intel (NASDAQ:<a href="https://investorplace.com/stock-quotes/intc-stock-quote/">INTC</a>), a firm I previously noted had lost almost 50% of its market value in a month.



The reasons for Intel&rsquo;s decline are obvious&hellip; at least in hindsight:



<ul><li>Innovation. In 2018, the company failed to deliver its 10-nanometer CPU, and has been catching up with subsequent standards ever since.</li>



<li>Competition. Arm architecture is now rivaling Intel&rsquo;s x86 platform in performance; some believe Intel could lose as much as 50% market share in CPUs from this.</li>



<li>Strategy. Intel has lagged GPU makers in developing AI-specific chips, leaving the sector wide open for players like Nvidia and Advanced Micro Devices (NASDAQ:<a href="https://investorplace.com/stock-quotes/amd-stock-quote/">AMD</a>).</li>
</ul>Perhaps worst of all, Intel&rsquo;s latest products appear to have been rushed. Many of its 13th and 14th generation CPUs are allegedly causing instabilities in both desktops and servers.



However, selloffs can sometimes go too far. As InvestorPlace.com&rsquo;s David Moadel wrote last week, <a href="https://investorplace.com/2024/08/intc-bloodbath-aftermath-buy-intel-stock-because-no-one-else-wants-to/">it&rsquo;s time to buy Intel&rsquo;s stock because no one else wants to</a>:




At this point, there&rsquo;s practically nothing left for Intel&rsquo;s shareholders to fear&hellip;



It&rsquo;s hard to envision the rainbow that&rsquo;s coming when it&rsquo;s storming. Intel is going through a rough period, but Intel CEO Pat Gelsinger assured that the aforementioned decisions (layoffs, dividend suspension) were &ldquo;painful and hard&rdquo; but necessary&hellip;



Unless you really think Intel&rsquo;s headed for Chapter 11, now&rsquo;s the time to exercise your contrarian muscles and buy a few shares.




Gelsinger is also putting his money where his mouth is. This week, the veteran executive bought 12,500 shares of his company&rsquo;s stock. And he might be onto something. Prometheus awards Intel a score of 85, suggesting that the selloff has finally gone too far.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.



Thomas Yeung is a market analyst and portfolio manager of the Omnia Portfolio, the highest-tier subscription at InvestorPlace. He is the former editor of Tom Yeung&rsquo;s Profit &amp; Protection, a free e-letter about investing to profit in good times and protecting gains during the bad.
<div>Thomas Yeung is a market analyst and portfolio manager of the Omnia Portfolio, the highest-tier subscription at InvestorPlace. He is the former editor of Tom Yeung&rsquo;s Profit &amp; Protection, a free e-letter about investing to profit in good times and protecting gains during the bad.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/5-tech-stocks-to-buy-on-the-rebound/">5 Tech Stocks to Buy on the Rebound</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

5 Tech Stocks to Buy on the Rebound

THE LAWSUIT: A class action securities lawsuit was filed against Symbotic Inc. (SYM) that seeks to recover losses of Symbotic shareholders who were...

Symbotic Inc. Class Action: Levi & Korsinsky LLP Reminds Symbotic Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 14, 2024 – SYM

Industrial and financial stocks with the largest net increases in hedge fund popularity - GS

Craig-Hallum analyst Greg Palm assigned a Buy rating to the stock today. The company's shares closed yesterday at $22.27. Palm covers the Technolog...

Craig-Hallum Releases a Buy Rating on Symbotic (SYM)

AeroVironment soars to top industrial gainer of week, while Symbotic leads decliners

As the AI hype fuels the S&P 500 Index (SPX) surge, driven by AI-centric companies like Nvidia ($NVDA), the index has risen over 15% year-to-date. ...

Short Sellers Could be Targeting AI Stocks

In a report released today, Joseph C Giordano from TD Cowen maintained a Buy rating on Symbotic (SYM – Research Report), with a price target of $43...

Symbotic (SYM) Receives a Buy from TD Cowen

Symbotic Inc. falls after short report from Hunterbrook

Rocket Lab soars to top industrial gainer of week, Rentokil drops after profit warning

Powell Industries climbs to top industrial gainer of week, FedEx dips after earnings

ATKR

AVAV

CMPR

CSWI

CWST

EWBC

HUBG

IESC

KLAC

LOAR

LUMN

MRCY

PCTY

POWL

PYCR

RKLB

RYAAY

SMCI

STRL

Legal

Press Releases

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 15, 2024 in Symbotic Lawsuit – SYM

Lost Money on Symbotic Inc.(SYM)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm

SYM LAWSUIT ALERT: Levi & Korsinsky Notifies Symbotic Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

SYM Investors Have Opportunity to Lead Symbotic Inc. Securities Fraud Lawsuit

SYM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Symbotic, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 15, 2024 in Symbotic Inc. Lawsuit - SYM

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Symbotic, PDD Holdings, Extreme Networks, and Sprinklr and Encourages Investors to Contact the Firm

SYMBOTIC INC. (NASDAQ: SYM) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Symbotic Inc. Investors of Upcoming Deadline

Symbotic Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - SYM

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Symbotic

Symbotic (SYM) Forecast

Symbotic (NASDAQ:SYM) Stock, Quote.Headers.trade-ideas